National Cancer Institute Purchases two Waters Corporation UPLC-MS Systems

April 1, 2009

The National Cancer Institute's Center for Cancer Research (Bethesda, Maryland), purchased a Waters ACQUITY UPLC®/Synapt High Definition MS (HDMSTM) and Waters ACQUITY® UPLC/XevoTM TQ MS Systems for its metabolomics research programs.

The National Cancer Institute's Center for Cancer Research (Bethesda, Maryland), purchased a Waters ACQUITY UPLC®/Synapt High Definition MS (HDMSTM) and Waters ACQUITY® UPLC/XevoTM TQ MS Systems for its metabolomics research programs. The research is aimed at discovering small molecule metabolites, or biomarkers, associated with cancer susceptibility and diagnosis, treatment efficacy, and the adverse effects of medicines and other chemicals. Researchers are confident these tools will lead to a better understanding of the mechanisms of the disease and its diagnosis, treatment, and prevention.